ERBB2 and breast carcinoma: In order to preserve both the axillary and breast regions, neoadjuvant therapy (NAT) is typically administered as the initial treatment for cN1+ breast cancer, particularly in patients with HER-2-positive breast cancer and triple-negative breast cancer.